The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Expand Range of Essential Drugs, Limit Coverage of Off-Year Re-Pricing: FPMAJ Member Associations
Organizations affiliated with the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) each submitted a list of their requests for a hearing held by a new health ministry panel on comprehensive pharmaceutical measures on September 22. All groups stressed the…
To read the full story
Related Article
- Cost Rates of Drugs in Japan Worsen on Inflation, Weaker Yen: FPMAJ Survey
September 26, 2022
- Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
September 26, 2022
- Academic Experts Throw Candid Questions on Industry Structure, Pricing: Hearing
September 26, 2022
- Japan Generic Industry Prods Govt to Raise Drug Prices to Ensure Stable Supply
September 26, 2022
- Revamped Expert Panel Holds Industry Hearing, Discussions Center on Drug Price Gap
September 26, 2022
REGULATORY
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…